First Trial for Tylenol Liver Failure Lawsuit Postponed Following Recent Settlement Talks

While the first federal Tylenol lawsuits was expected to go before a jury this week, involving allegations that Johnson & Johnson failed to adequately warn about the risk of liver failure from side effects of Tylenol, the U.S. District Judge presiding over the litigation has postponed the trial, following a series of recent settlement conferences. 

Trial was scheduled to begin today in a case brought by Rana Terry, whose sister died from liver failure that was allegedly caused by use of Extra Strength Tylenol. The case was selected as the first in a series of early trial dates designed to gauge how juries may respond to certain evidence and testimony that is likely to be repeated in the litigation.

There are currently at least 217 similar Tylenol lawsuits pending throughout the federal court system, which have been centralized for coordinated discovery and pretrial proceedings before U.S. District Judge Lawrence Stengel in the Eastern District of Pennsylvania, as part of an MDL, or multidistrict litigation.

Each of the complaints raise similar allegations, indicating that Johnson & Johnson built a false reputation that Tylenol is a safe and effective medications by withholding important safety information about the risk of liver damage, which may have caused individuals throughout the United States to suffer severe liver failure, often resulting in death or the need for a liver transplant.

In case management order (pdf) issued on September 15, Judge Stengel ordered that the trial date be continued to a date that will be determined in the future.

No specific reason for the delay was disclosed in the court filing, but the parties have engaged in a number of Tylenol settlement conferences in recent weeks, which may have included discussions about resolving the Terry case specifically, or the litigation as a whole.

While no details from those settlement conferences have been released, Johnson & Johnson may have motivation to settle Tylenol cases before trial, at which evidence may be presented that suggests the company withheld important safety information for decades about their popular pain medication.

Tylenol is one of the most widely used painkiller medications in the United States, which has been used by millions of Americans. However, federal health officials have previously suggested that Tylenol and other acetaminophen drugs may be responsible for more than 50,000 emergency room visits each year, including 25,000 hospitalizations and over 450 deaths annually due to liver failure. Plaintiffs allege that Johnson & Johnson has worked for decades to build a false reputation that Tylenol is safe, which may have caused many unnecessary deaths and severe injuries due to over use of acetaminophen.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera.
A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children.
Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer.